Total Payments
$221,327
2024 Payments
$1,815
Companies
18
Transactions
163
Payment Breakdown by Category
Research$187,083 (84.5%)
Other$13,020 (5.9%)
Travel$11,065 (5.0%)
Consulting$6,480 (2.9%)
Food & Beverage$3,604 (1.6%)
Education$75.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $187,083 | 48 | 84.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,020 | 5 | 5.9% |
| Travel and Lodging | $11,065 | 38 | 5.0% |
| Consulting Fee | $6,480 | 2 | 2.9% |
| Food and Beverage | $3,604 | 67 | 1.6% |
| Education | $75.74 | 3 | 0.0% |
Payments by Type
Research
$187,083
48 transactions
General
$34,245
115 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arbor Pharmaceuticals, Inc. | $142,972 | 8 | $0 (2019) |
| Valneva Austria GmbH | $31,415 | 5 | $0 (2022) |
| Shire North American Group Inc | $27,501 | 75 | $0 (2018) |
| Eli Lilly and Company | $4,651 | 12 | $0 (2023) |
| Circassia Pharmaceuticals Inc | $3,030 | 3 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $2,228 | 11 | $0 (2017) |
| Supernus Pharmaceuticals, Inc. | $2,160 | 9 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $2,048 | 7 | $0 (2017) |
| Amgen Inc. | $1,777 | 4 | $0 (2024) |
| ModernaTX, Inc. | $1,610 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,815 | 5 | Amgen Inc. ($1,777) |
| 2023 | $2,131 | 9 | ModernaTX, Inc. ($1,610) |
| 2022 | $32,045 | 8 | Valneva Austria GmbH ($31,415) |
| 2021 | $455.79 | 3 | Eli Lilly and Company ($432.69) |
| 2020 | $1,876 | 4 | Eli Lilly and Company ($1,876) |
| 2019 | $143,229 | 16 | Arbor Pharmaceuticals, Inc. ($142,961) |
| 2018 | $539.91 | 14 | Intuitive Surgical, Inc. ($211.67) |
| 2017 | $39,236 | 104 | Shire North American Group Inc ($27,334) |
All Payment Transactions
163 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $38.86 | General |
| Category: Dermatology | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $1,203.20 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $281.37 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $275.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/17/2023 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $517.85 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $447.99 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $349.86 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $206.72 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $36.00 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $27.97 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $23.58 | General |
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $494.72 | General |
| 02/14/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: Musculoskeletal | ||||||
| 09/23/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $5,980.46 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 08/01/2022 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 06/07/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $3,045.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $297.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 03/15/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $5,700.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/08/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $15,190.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 02/08/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/23/2021 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $23.10 | General |
| 05/31/2021 | Eli Lilly and Company | — | — | In-kind items and services | $400.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | ||||||
| 02/10/2021 | Eli Lilly and Company | — | — | In-kind items and services | $32.69 | Research |
| Study: A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $142,961 | 7 |
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $31,415 | 5 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $3,030 | 3 |
| Evaluation of SPN-812 ER 100 and 200 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo- Controlled, Pivotal Trial | Supernus Pharmaceuticals, Inc. | $2,160 | 9 |
| A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Regeneron Pharmaceuticals, Inc. | $2,048 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $1,535 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $1,048 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | Eli Lilly and Company | $677.44 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $656.00 | 3 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $656.00 | 3 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $420.01 | 2 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $272.95 | 2 |
| AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | Eli Lilly and Company | $150.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $52.80 | 1 |
About Dr. Mark Turner, MD
Dr. Mark Turner, MD is a Family Medicine healthcare provider based in Meridian, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962443101.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Turner, MD has received a total of $221,327 in payments from pharmaceutical and medical device companies, with $1,815 received in 2024. These payments were reported across 163 transactions from 18 companies. The most common payment nature is "" ($187,083).
Ad
Practice Information
- Specialty Family Medicine
- Location Meridian, ID
- Active Since 06/09/2006
- Last Updated 03/07/2023
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1962443101
Products in Payments
- AR19 (Drug) $142,961
- MYDAYIS (Drug) $27,454
- KRYSTEXXA (Biological) $1,777
- CNP520 (Drug) $1,059
- Da Vinci Surgical System (Device) $331.76
- VRAYLAR (Drug) $74.80
- Xeomin (Biological) $65.32
- VYVANSE (Drug) $46.92
- AXIS (Biological) $43.87
- AUSTEDO (Drug) $15.85
- RESTORELLE (Device) $13.48
- Myrbetriq (Drug) $11.70
- Otovel (Drug) $11.06
- ANORO (Drug) $10.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Meridian
David Butuk, Md, MD
Family Medicine — Payments: $303,128
Family Medicine $303,128
Andrea Goodwin, M.d, M.D
Family Medicine — Payments: $194,380
Family Medicine $194,380
Timothy Mchugh, Md, MD
Family Medicine — Payments: $182,889
Family Medicine $182,889
Dr. Mark Macumber, Md, MD
Family Medicine — Payments: $37,593
Family Medicine $37,593
Ginger Allen, Md, MD
Family Medicine — Payments: $19,559
Family Medicine $19,559
Dr. Douglas Phillips, M.d, M.D
Family Medicine — Payments: $13,843
Family Medicine $13,843